From January 1, 2023 to March 31, 2023, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 3,353,758 shares, representing 0.58% for CNY 77.29 million under the buyback announced on October 21, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.15 CNY | -1.84% |
|
-2.10% | -7.16% |
Jun. 12 | Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification | MT |
Apr. 26 | Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.16% | 1.46B | |
-9.74% | 11.58B | |
-9.80% | 8.21B | |
+5.08% | 5.77B | |
+27.84% | 5.55B | |
-15.47% | 3.83B | |
+8.47% | 2.65B | |
-63.81% | 2.36B | |
-9.24% | 2.27B | |
+21.21% | 2.11B |
- Stock Market
- Equities
- 688289 Stock
- News Sansure Biotech Inc.
- Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.